Translate Bio to Present at the Bank of America Securities Virtual 2020 Healthcare Conference
Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, has announced that CEO Ronald Renaud will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on May 14, 2020, at 9:00 a.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Translate Bio (Nasdaq: TBIO), a clinical-stage mRNA therapeutics company, has announced that CEO Ronald Renaud will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on May 14, 2020, at 9:00 a.m. ET. This session will be available via live webcast on the Company's website, with a replay accessible for 30 days after the event.
Translate Bio is notably focused on developing transformative medicines for diseases linked to protein dysfunction, including a lead program targeting cystic fibrosis currently in a Phase 1/2 clinical trial.
Details
News Market Reaction – TBIO
The recorded move for TBIO in the trading session of this news was +14.63%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
LEXINGTON, Mass., May 12, 2020 (GLOBE NEWSWIRE) -- Translate Bio (Nasdaq: TBIO), a clinical-stage messenger RNA (mRNA) therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction, today announced that Ronald Renaud, chief executive officer, will participate in a fireside chat at the Bank of America Securities Virtual 2020 Health Care Conference on Thursday, May 14, 2020, at 9:00 a.m. ET.
A live webcast of the session will be accessible through the “Events and Presentations” page of the Company's website at investors.translate.bio. A replay of the webcast will be archived on the Translate Bio’s website for 30 days following the presentation.
About Translate Bio
Translate Bio is a clinical-stage mRNA therapeutics company developing a new class of potentially transformative medicines to treat diseases caused by protein or gene dysfunction. Translate Bio is primarily focused on applying its technology to treat pulmonary diseases caused by insufficient protein production or where the reduction of proteins can modify disease. Translate Bio’s lead program is being developed as a treatment for cystic fibrosis (CF) and is in a Phase 1/2 clinical trial. The Company also believes its technology is applicable to a broad range of diseases, including diseases that affect the liver. Additionally, the platform may be applied to various classes of treatments, such as therapeutic antibodies or vaccines in areas such as infectious disease and oncology. For more information about the Company, please visit www.translate.bio or on Twitter at @TranslateBio.
Contacts for Translate Bio
| Investors | Media | |
| Teri Dahlman | Maura Gavaghan | |
| tdahlman@translate.bio | mgavaghan@translate.bio | |
| 857-242-7792 | 857-242-7789 |
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.